An NKG2D-Fc-IL2 DNA vaccine in combination with a therapeutic human papillomavirus type 16/E7 peptide vaccine was able to result in accumulation and proliferation of E7-specific T cells at the tumor site and reduced tumor growth that resulted in prolonged survival of tumor-bearing mice [95]. The gene discussed is KLRK1; the disease is neoplasm.